urea has been researched along with Atrial Flutter in 14 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Atrial Flutter: Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
Excerpt | Relevance | Reference |
---|---|---|
"In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction." | 9.51 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. ( Claggett, BL; Corbalan, R; Diaz, R; Felker, GM; Filippatos, G; Goudev, AR; Heitner, SB; Kupfer, S; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Miao, ZM; Serpytis, P; Solomon, SD; Suter, T; Teerlink, JR; Yilmaz, MB; Zannad, F, 2022) |
"We investigated for the first time the suitability of landiolol, an ultra-short-acting β1-specific β-blocker, for the treatment of atrial fibrillation/atrial flutter (AF/AFL) in Caucasian patients." | 9.30 | Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients. ( Domanovits, H; Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Stix, G; Trebs, M; Unger, M; Wolzt, M, 2019) |
" Landiolol, an ultrashort-acting β-blocker, was approved in 2013 for tachyarrhythmias in adult patients with heart failure." | 9.24 | Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial. ( Horigome, H; Iwamoto, M; Miura, M; Miyazaki, A; Nagano, T; Ohashi, N; Ono, H; Sagawa, K; Sakaguchi, H; Sumitomo, N; Suzuki, T; Takahashi, K; Takamuro, M; Takigiku, K; Tokunaga, C; Ueda, H; Ushinohama, H; Yoshimoto, J, 2017) |
" The J-Land study was conducted to compare the efficacy and safety of landiolol, an ultra-short-acting β-blocker, with those of digoxin for swift control of tachycardia in AF/AFL in patients with LV dysfunction." | 9.17 | Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). ( Aiba, T; Atarashi, H; Daimon, T; Fujino, K; Hori, M; Ikeda, T; Imai, Y; Inoue, H; Kinugawa, K; Kitakaze, M; Nagai, R; Nagano, T; Okamura, T; Sakamoto, A; Seino, Y; Shimizu, W; Yamashita, T, 2013) |
"Consecutive patients with cardiac dysfunction who received landiolol (continuous intravenous infusion, starting at 1μg/kg/min) for atrial fibrillation or atrial flutter in routine clinical practice in Japan were enrolled between June 2014 and May 2016." | 7.91 | A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. ( Mizutani, H; Nakasu, Y; Sumitani, K; Yamashita, T, 2019) |
"The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post-operative atrial fibrillation or atrial flutter after major pulmonary resection." | 7.78 | Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. ( Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I, 2012) |
"The purpose of this study was to investigate the efficacy of landiolol hydrochloride, a short-acting beta(1) blocker, by initiating its administration at a low dose (5 microg kg(-1) min(-1)) in patients with postoperative supraventricular arrhythmia." | 7.75 | Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. ( Fukutomi, T; Nishimori, H; Radhakrishnan, G; Sasaguri, S; Wariishi, S; Yamamoto, M; Yamashita, K, 2009) |
"In GALACTIC-HF, the cardiac myosin activator omecamtiv mecarbil compared with placebo reduced the risk of heart failure events or cardiovascular death in patients with heart failure with reduced ejection fraction." | 5.51 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. ( Claggett, BL; Corbalan, R; Diaz, R; Felker, GM; Filippatos, G; Goudev, AR; Heitner, SB; Kupfer, S; Malik, FI; Mareev, V; McMurray, JJV; Metra, M; Miao, ZM; Serpytis, P; Solomon, SD; Suter, T; Teerlink, JR; Yilmaz, MB; Zannad, F, 2022) |
"Landiolol was ineffective in the majority of AFl/AT patients." | 5.51 | Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction. ( Fujimoto, Y; Hayashi, H; Hayashi, M; Ito-Hagiwara, K; Iwasaki, YK; Maru, E; Oka, E; Shimizu, W; Yamamoto, T; Yodogawa, K, 2019) |
"We investigated for the first time the suitability of landiolol, an ultra-short-acting β1-specific β-blocker, for the treatment of atrial fibrillation/atrial flutter (AF/AFL) in Caucasian patients." | 5.30 | Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients. ( Domanovits, H; Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Stix, G; Trebs, M; Unger, M; Wolzt, M, 2019) |
" Landiolol, an ultrashort-acting β-blocker, was approved in 2013 for tachyarrhythmias in adult patients with heart failure." | 5.24 | Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial. ( Horigome, H; Iwamoto, M; Miura, M; Miyazaki, A; Nagano, T; Ohashi, N; Ono, H; Sagawa, K; Sakaguchi, H; Sumitomo, N; Suzuki, T; Takahashi, K; Takamuro, M; Takigiku, K; Tokunaga, C; Ueda, H; Ushinohama, H; Yoshimoto, J, 2017) |
"Results from the multicenter trial (J-Land study) of landiolol versus digoxin in atrial fibrillation (AF) and atrial flutter (AFL) patients with left ventricular (LV) dysfunction revealed that landiolol was more effective for controlling rapid HR than digoxin." | 5.19 | Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. ( Aiba, T; Atarashi, H; Daimon, T; Fujino, K; Hori, M; Ikeda, T; Imai, Y; Inoue, H; Kinugawa, K; Kitakaze, M; Nagai, R; Nagano, T; Okamura, T; Sakamoto, A; Seino, Y; Shimizu, W; Yamashita, T, 2014) |
" The J-Land study was conducted to compare the efficacy and safety of landiolol, an ultra-short-acting β-blocker, with those of digoxin for swift control of tachycardia in AF/AFL in patients with LV dysfunction." | 5.17 | Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). ( Aiba, T; Atarashi, H; Daimon, T; Fujino, K; Hori, M; Ikeda, T; Imai, Y; Inoue, H; Kinugawa, K; Kitakaze, M; Nagai, R; Nagano, T; Okamura, T; Sakamoto, A; Seino, Y; Shimizu, W; Yamashita, T, 2013) |
"Consecutive patients with cardiac dysfunction who received landiolol (continuous intravenous infusion, starting at 1μg/kg/min) for atrial fibrillation or atrial flutter in routine clinical practice in Japan were enrolled between June 2014 and May 2016." | 3.91 | A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. ( Mizutani, H; Nakasu, Y; Sumitani, K; Yamashita, T, 2019) |
"The response to continuous intravenous infusion of landiolol was evaluated in 25 patients who developed post-operative atrial fibrillation or atrial flutter after major pulmonary resection." | 3.78 | Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. ( Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I, 2012) |
"The purpose of this study was to investigate the efficacy of landiolol hydrochloride, a short-acting beta(1) blocker, by initiating its administration at a low dose (5 microg kg(-1) min(-1)) in patients with postoperative supraventricular arrhythmia." | 3.75 | Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. ( Fukutomi, T; Nishimori, H; Radhakrishnan, G; Sasaguri, S; Wariishi, S; Yamamoto, M; Yamashita, K, 2009) |
"Landiolol was ineffective in the majority of AFl/AT patients." | 1.51 | Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction. ( Fujimoto, Y; Hayashi, H; Hayashi, M; Ito-Hagiwara, K; Iwasaki, YK; Maru, E; Oka, E; Shimizu, W; Yamamoto, T; Yodogawa, K, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.14) | 29.6817 |
2010's | 12 (85.71) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
Authors | Studies |
---|---|
Solomon, SD | 1 |
Claggett, BL | 1 |
Miao, ZM | 1 |
Diaz, R | 1 |
Felker, GM | 1 |
McMurray, JJV | 1 |
Metra, M | 1 |
Corbalan, R | 1 |
Filippatos, G | 1 |
Goudev, AR | 1 |
Mareev, V | 1 |
Serpytis, P | 1 |
Suter, T | 1 |
Yilmaz, MB | 1 |
Zannad, F | 1 |
Kupfer, S | 1 |
Heitner, SB | 1 |
Malik, FI | 1 |
Teerlink, JR | 1 |
Stix, G | 1 |
Wolzt, M | 1 |
Domanovits, H | 1 |
Kadlecová, P | 1 |
Husch, B | 1 |
Trebs, M | 1 |
Hodisch, J | 1 |
Unger, M | 1 |
Krumpl, G | 1 |
Oka, E | 2 |
Iwasaki, YK | 2 |
Maru, E | 1 |
Fujimoto, Y | 1 |
Ito-Hagiwara, K | 1 |
Hayashi, H | 1 |
Yamamoto, T | 1 |
Yodogawa, K | 1 |
Hayashi, M | 1 |
Shimizu, W | 4 |
Nitta, D | 1 |
Imamura, T | 1 |
Yamashita, T | 4 |
Nakasu, Y | 1 |
Mizutani, H | 1 |
Sumitani, K | 1 |
Momomura, S | 1 |
Nagai, R | 2 |
Kinugawa, K | 2 |
Inoue, H | 2 |
Atarashi, H | 2 |
Seino, Y | 2 |
Aiba, T | 2 |
Kitakaze, M | 2 |
Sakamoto, A | 2 |
Ikeda, T | 2 |
Imai, Y | 2 |
Daimon, T | 2 |
Fujino, K | 2 |
Nagano, T | 3 |
Okamura, T | 2 |
Hori, M | 2 |
Saitoh, T | 1 |
Matsushita, M | 1 |
Takata, J | 1 |
Haruyama, N | 1 |
Arashi, T | 1 |
Mae, T | 1 |
Sumitomo, N | 1 |
Horigome, H | 1 |
Miura, M | 1 |
Ono, H | 1 |
Ueda, H | 1 |
Takigiku, K | 1 |
Yoshimoto, J | 1 |
Ohashi, N | 1 |
Suzuki, T | 1 |
Sagawa, K | 1 |
Ushinohama, H | 1 |
Takahashi, K | 1 |
Miyazaki, A | 1 |
Sakaguchi, H | 1 |
Iwamoto, M | 1 |
Takamuro, M | 1 |
Tokunaga, C | 1 |
Wariishi, S | 1 |
Yamashita, K | 1 |
Nishimori, H | 1 |
Fukutomi, T | 1 |
Yamamoto, M | 1 |
Radhakrishnan, G | 1 |
Sasaguri, S | 1 |
Nakano, T | 1 |
Shimizu, K | 1 |
Kawashima, O | 1 |
Kamiyoshihara, M | 1 |
Nagashima, T | 1 |
Ibe, T | 1 |
Takeyoshi, I | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)[NCT02929329] | Phase 3 | 8,256 participants (Actual) | Interventional | 2017-01-06 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire with a 2-week recall period that includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score. Scores are represented on a 0-to-100-point scale, where lower scores represent more frequent and severe symptoms and scores of 100 indicate no symptoms.~The change from baseline in KCCQ TSS was analyzed separately for each randomization setting (inpatient and outpatient).~Least squares means are from the mixed model which includes baseline total symptom score value, region, baseline eGFR, scheduled visit, treatment group and interaction of treatment with scheduled visit as covariates." (NCT02929329)
Timeframe: Baseline and Week 24
Intervention | scores on a scale (Least Squares Mean) |
---|---|
Placebo: Oupatients | 6.29 |
Omecamtiv Mecarbil: Outpatients | 5.83 |
Placebo: Inpatients | 21.15 |
Omecamtiv Mecarbil: Inpatients | 23.65 |
"All events were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.~Time to all-cause death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with an event are reported. Events that occurred up to the earliest of last confirmed survival status date or analysis cut-off date (07 August 2020) are included." (NCT02929329)
Timeframe: From randomization up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Intervention | percentage of participants (Number) |
---|---|
Placebo | 25.9 |
Omecamtiv Mecarbil | 25.9 |
"Cardiovascular death includes acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes.~All deaths were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials.~Time to cardiovascular death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported." (NCT02929329)
Timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Intervention | percentage of participants (Number) |
---|---|
Placebo | 19.4 |
Omecamtiv Mecarbil | 19.6 |
"The primary outcome was a composite of a heart-failure (HF) event or cardiovascular (CV) death, whichever occurred first, in a time-to-event analysis.~A heart-failure event was defined as an urgent clinic visit, emergency department visit, or hospitalization for subjectively and objectively worsening heart failure leading to treatment intensification beyond a change in oral diuretic therapy.~All deaths and HF events were adjudicated by an independent external clinical events committee (CEC) at the Duke Clinical Research Institute, using standardized definitions based on the recent American College of Cardiology/American Heart Association (ACC/AHA) standards for endpoint definitions in cardiovascular clinical trials.~Time to cardiovascular death or first HF event was analyzed using Kaplan-Meier (KM) methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported." (NCT02929329)
Timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Intervention | percentage of participants (Number) |
---|---|
Placebo | 39.1 |
Omecamtiv Mecarbil | 37.0 |
"A HF hospitalization is defined as an event that met all of the following criteria:~The participant was admitted to the hospital with a primary diagnosis of HF;~The length of stay in the hospital extended for at least 24 hours;~The participant exhibited documented new or worsening symptoms due to HF on presentation;~The participant had objective evidence of new or worsening HF;~The participant received initiation or intensification of treatment specifically for HF, including an intravenous diuretic or vasoactive agent, mechanical or surgical intervention, or mechanical fluid removal.~Events were adjudicated by an independent external CEC at the Duke Clinical Research Institute using standardized definitions based on the ACC/AHA standards for endpoint definitions in CV clinical trials.~Time to first HF hospitalization was analyzed using KM methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event is reported." (NCT02929329)
Timeframe: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Intervention | percentage of participants (Number) |
---|---|
Placebo | 28.7 |
Omecamtiv Mecarbil | 27.7 |
5 trials available for urea and Atrial Flutter
Article | Year |
---|---|
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Topics: Atrial Fibrillation; Atrial Flutter; Digoxin; Heart Failure; Humans; Quality of Life; Stroke Volume; | 2022 |
Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Humans; Middle Aged; Morpholines; Pilo | 2019 |
Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Flut | 2013 |
Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; Drug | 2014 |
Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschoo | 2017 |
9 other studies available for urea and Atrial Flutter
Article | Year |
---|---|
Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Humans; Male; Middle Aged; Morpho | 2019 |
What Determines the Response to Landiolol?
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction | 2019 |
What Determines the Response to Landiolol? - Reply.
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction | 2019 |
A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Hea | 2019 |
Acute rate control in atrial fibrillation with left ventricular dysfunction.
Topics: Adrenergic beta-1 Receptor Antagonists; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Female; Hea | 2013 |
Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Atrial Fibrillation; Atr | 2015 |
Alteration of fatal 1:1 conducted atrial flutter to less conducted ratio by landiolol infusion.
Topics: Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Male; Morpholin | 2016 |
Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; | 2009 |
Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter | 2012 |